Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes
The Danish healthcare company’s stock slumped on Friday after it announced the Phase 3 trial failure.
Overview
The Danish healthcare company’s stock slumped on Friday after it announced the Phase 3 trial failure.
Source
Originally published at www.marketwatch.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.